Kornitzer Cuts Stryker Stake 59.8% as Analysts Trim Targets to $342

Kornitzer Capital Management Inc. KS cut its Stryker Corporation (NYSE:SYK) position by 59.8% in the third quarter, an SEC disclosure shows. The firm sold 2,294 shares and kept 1,542, worth $425,000 at the most recent filing date. That is a near-total exit, not a rebalance — and the filing says nothing about why.

The disclosure lands days after a quarter that fell short on both lines. On Thursday, October 29, Stryker reported $3.52 EPS against a consensus of $3.55, a miss of $0.03. Revenue of $6.52 billion came in $100 million below the $6.62 billion analysts expected. Takeaway: one institutional seller acted after a quarter that missed twice.

Did anyone else sell?

Most other named institutions moved the other way, though in sizes too small to signal conviction:

• Community Bank & Trust Waco Texas added 31 shares, up 2.3%, to 1,395 shares worth $439,000.
• Cornerstone Financial Management LLC added 31 shares, up 66.0%, to 78 shares worth $25,000.
• NWF Advisory Services Inc. added 33 shares, up 2.3%, to 1,472 shares worth $463,000.
• Private Harbour Investment Management & Counsel LLC added 34 shares, up 0.9%, to 3,927 shares worth $1,236,000.
• Natural Investments LLC added 34 shares, up 1.2%, to 2,789 shares worth $878,000.

Institutions and hedge funds own 77.09% of the stock. Note what the aggregate figure does not say: it does not show net direction across all holders, only that five small buyers and one large cutter filed changes. Takeaway: the buying is real but tiny; the selling is the only move large enough to count.

What do the numbers say about the stock?

SYK opened at $324.00 on Wednesday. Market capitalization stands at $123.34 billion, with a price-to-earnings ratio of 34.50, a PEG ratio of 2.24 and a beta of 0.78. The 50-day simple moving average sits at $292.25; the 200-day at $323.23. The stock has traded between a twelve-month low of $267.00 and a twelve-month high of $389.33.

The balance sheet reads stable: a current ratio of 2.18, a quick ratio of 1.30, debt-to-equity of 0.60. Profitability held up — return on equity of 23.74%, net margin of 13.78%, revenue up 7.6% year over year, EPS up from $3.19 a year earlier. Analysts forecast $14.84 EPS for the current fiscal year. Takeaway: a 34.5x multiple against a missed quarter is the tension an investor has to price.

How did analysts respond?

Five shops cut their numbers on Friday, October 30:

• Canaccord Genuity downgraded from Buy to Hold and cut its target from $385.00 to $300.00.
• Raymond James kept Outperform but lowered its target from $370.00 to $323.00.
• JPMorgan Chase & Co. set Overweight and cut its target from $350.00 to $340.00.
• Royal Bank of Canada kept Outperform and dropped its target from $420.00 to $375.00.
• TD Cowen held at Hold and cut its target from $298.00 to $290.00.

Of twenty-eight analysts tracked, twenty-one rate the stock Buy and seven Hold, for a consensus of Moderate Buy and an average target of $342.19 — roughly 5.6% above Wednesday's open. Every single shop cut. None raised. Takeaway: the consensus target sits above the price, but it got there by moving down.

What are insiders doing?

Two disclosures stand out. Insider Debra King sold 826 shares on Tuesday, August 18 at an average of $336.30, totaling $277,783.80, leaving 6,210 shares worth about $2,088,423 — an 11.74% cut in her position. Insider Dylan Crotty sold 441 shares on Friday, August 21 at $328.61, totaling $144,917.01, leaving 6,102 shares worth roughly $2,005,178.22, a 6.74% reduction.

The broader pattern is larger: insiders sold 901,267 shares worth $297,123,701 over the last ninety days. Insiders own 4.60% of the company. The filings record the sales; they do not record reasons. Takeaway: nearly $300 million of insider selling preceded the miss, and the paperwork is silent on motive.

Stryker develops and sells medical technology — orthopedic implants, surgical and neurotechnology and spine products, patient-handling and emergency medical equipment — to healthcare providers in the United States and abroad. The stock sits 17% below its high, between a cut at one fund and a moderate-buy consensus still marking it down.